This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Targeting TAK1 protein to treat systemic sclerosis

Targeting TAK1 protein to treat systemic sclerosis
Credit: JCI Insight (2023). DOI: 10.1172/jci.insight.165358

Systemic sclerosis is the scaring of multiple organs within the body resulting in difficulty in functioning for these organs. The disease can become deadly if the organ scaring isn't treated properly.

Researchers at the University of Michigan Health System have identified a protein in the disease that may be a new target for treatment.

In the study titled "Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis," published in JCI Insight, a team of researchers from the John Varga, M.D. lab identified that blocking the TAK1 protein using a new called HS-276 can stop the production of collogen that causes scar-forming cells in systemic .

"HS-276 significantly reduced the expression of collagen, and fibrotic disease associated molecular patterns including Fibronectin EDA and Tenascin-C in SSc explanted fibroblasts," said Swarna Bale, first author of the study.

"The reduced TAK1 activation in SSc skin biopsies suggested that, if it can be further thoroughly investigated, this can be a leading anti-fibrotic drug molecule."

HS-276 showed reduced collagen levels in as well as a reduction in progression of systemic sclerosis. This was evidenced from reduced levels of TAK1 activation as well as reducing fibrotic associated molecular patterns including Fibronectin EDA and Tenascin-C.

This drug has been studied with arthritis in the past and has been effective in treating collagen-induced arthritis.

The next step is to begin testing the efficiency of the HS-276 drug in genetic mice models and investigating the reproducibility of the antifibrotic effects of the drug in the mice models used.

More information: Swarna Bale et al, Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis, JCI Insight (2023). DOI: 10.1172/jci.insight.165358

Journal information: JCI Insight
Citation: Targeting TAK1 protein to treat systemic sclerosis (2023, July 28) retrieved 19 June 2024 from https://medicalxpress.com/news/2023-07-tak1-protein-sclerosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers target protein that can slow down muscular dystrophy

24 shares

Feedback to editors